House seeks interview with former FDA leader © Washington Examiner/Pool The House subcommittee investigating the U.S. response to the coronavirus wants to question Stephen Hahn, former President Trump's Food and Drug Administration commissioner, about attempts to improperly interfere with the agency's review of COVID-19 therapeutics and vaccines, and to boost drugs with minimal benefit. The committee on Monday sent a letter to Hahn asking him to sit for an interview on Dec. 16, and to provide documents and communications by Dec. 6. The FDA faced an onslaught from political appointees across the government to fast track approvals of therapeutics and vaccines that would show the Trump administration had the pandemic under control, including hydroxychloroquine and convalescent plasma. "Given the sustained campaigns to promote the use of dubious coronavirus treatments, the Select Subcommittee seeks to understand the full extent and impact of Trump Administration officials’ efforts to influence these FDA decisions," panel chairman Rep. James Clyburn (D-S.C.) wrote. Seeking answers: The committee wants information about Trump officials' efforts to promote the use of chloroquine and hydroxychloroquine, antimalarial drugs that Trump touted as a miracle cure, despite no evidence. The agency granted emergency use authorization for hydroxychloroquine in late March of 2020. The panel cited messages between Hahn and other agency officials expressing concerns that hydroxychloroquine was ineffective and potentially dangerous; the FDA did not formally revoke the authorization until June. The panel also wants to learn more about the authorization of convalescent plasma. The FDA rushed to issue an emergency use authorization for plasma on August 23, 2020, after Trump pressured the agency to move faster in pushing out coronavirus treatments and vaccines, despite scientists saying more research was needed. Read more here. |
No comments:
Post a Comment